73 results about "Tetramethylurea" patented technology

The invention discloses a method for producing photochromic composite film which comprises, mixing the inorganic aqueous solution with organic molecular solution and agitating, forming films on clean substrates with the obtained sol by means of casting method or rotary coating method, the inorganic substance is molybdic acid, sodium molybdate, amine molybdate, phosphomolybdic acid or silicomolybdic acid, the organic molecule is N-methyl pyrrolidone, tetramethylurea, polyvinyl pyrrolidon, polyacrylamide, polyacrylic acid, or polyvinyl alcohol.

The invention discloses a method for preparing 2,5-furandicarboxylic acid (FDCA) from sugar. The method specifically includes converting hexacarbon saccharide as a raw material into 5-hydroxymethylfurfural (5-HMF) through a reaction in a tetramethylurea solvent in the presence of an acid as a catalyst, converting the 5-HMF into the FDCA through a reaction, and precipitating a product from the system that can be recycled. The method has the advantages of high product yield, simple process route and potential industrial application prospect.

The invention discloses a preparation method of biotin-modified and rare earth-doped inorganic fluorescent nanoparticles. The method comprises the following steps: activating the carboxyl groups of biotin in a solvent of anhydrous N,N-dimethylformamide with benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIEA) as activators, reacting the activated carboxyl group with the amino groups of the nanoparticles to form amide bonds so as to achieve biotin modification on the surface of rare earth-doped inorganic fluorescent nanoparticles. The biotin-modified and rare earth-doped inorganic fluorescent nanoparticles prepared with the method provided by the invention can quickly and stably bind with avidins, and the specific luminescence of rare earth ions doped in the nanoparticles can give sensitive response to the binding, which indicates that the nano materials obtained by the preparation method have potentials of applications in the fields of biological labeling and immunological analysis.

Disclosed is an ink composition including: (1) a pigment; (2) a polymerization initiator having a content of 2% by mass or more with respect to a total amount of the composition and having a solubility with respect to pure water at 25° C. of 5 to 8 g / l; (3) a compound A that is at least one selected from the group consisting of dimethylacrylamide, diethylacrylamide, N-isopropylacrylamide, dimethylacetamide, N-ethylpyrrolidone, 1-cyclohexyl-2-pyrrolidone, 1-(2-hydroxyethyl)-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, tetramethylurea and gamma-valerolactone; (4) a polymerizable compound having two or more ethylenically unsaturated double bonds; and (5) water having a content of 50% by mass or more with respect to the total amount of the composition.

In order to overcome the problems of a plurality of by-products, low yield and difficulty in controlling of reaction conditions for a conventional preparation method of bis(fluorosulfonyl)imide, the invention provides a preparation method for the bis(fluorosulfonyl)imide. The preparation method comprises the following operation steps: preparing an S.nHF complex, wherein a compound S is one or moreselected from the group consisting of liquid ammonia, N,N'-dimethylformamide, N,N'-dimethylacetamide, hexamethylphosphoramide, 1-methyl-2-pyrrolidone, tetramethylurea, N,N'-dimethylpropylurea, 1,3-dimethyl-2-imidazolinone, 1,3-di-n-butyl-2-imidazolinone, melamine, poly(vinylpyridine) and an ester compound; and mixing the S.nHF complex with bis(chlorosulfonyl)imide, and collecting a fraction of the bis(fluorosulfonyl)imide. Meanwhile, the invention also discloses a preparation method for lithium bis(fluorosulfonyl)imide. The preparation method for the bis(fluorosulfonyl)imide provided by the invention can effectively reduce generation of by-products, and improves the yield of the bis(fluorosulfonyl)imide.

The invention provides lithium battery anode slurry mixing solvent and a method for preparing lithium battery anode slurry by using the solvent, and relates to the technical field of batteries. The lithium battery anode slurry mixing solvent is mixed solvent prepared by mixing N,N-dimethyl acetamide, dimethyl sulfoxide, tetramethylurea and trimethyl phosphate. The lithium battery anode slurry mixing solvent can be applied to a lithium battery anode slurry mixing technology, is low in raw material cost, green, environmentally friendly and good in safety performance, cannot generate irritative or poisonous gas or damage health of human bodies or bring environmental pollution when being decomposed, is easy to recycle, good in performance and free of hygroscopicity and can be applied and popularized and bring considerable social benefits and society benefits.

The invention relates to a multifunctional fluorescent probe having ESIPT and AIE properties and a preparation method and application thereof. The preparation method of the fluorescent probe includesthe steps that 2-picolinic acid is dissolved in dried dichloromethane, benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate is added for stirring for 30 minutes, then 2-(2'-aminophenyl)benzothiazole and triethylamine are added, and the whole mixture is stirred at the room temperature and placed overnight; after a reaction is completed, a solvent is evaporated and removed under reduced pressure, residues are subjected to column chromatography isolation, and the fluorescent probe N-(2-(2'-benzothiazolyl)phenyl)picolinamide is obtained. A synthesis method of the fluorescent probe is simple, a product separation and purification process is simple, and the fluorescent probe has the ESIPT and AIE properties, can be used for monitoring analysis and tracing of copper ions and pyrophosphatein a water environment system, and has high sensitivity in determination of target ions.

The invention discloses a preparation method for a PVDF porous nanofiber membrane. The preparation method comprises the steps that (1) alkyl alcohol amine poly oxygen ethane ether, lithium perchlorate, acetone, lithium metaborate, tetramethylurea, lithium oxalate, single-walled carbon nanotubes, lithium lactate, lithium citrate, polyvinylidene fluoride, vinyl trimethoxy silane, lithium phosphate, methyl ethyl acetone, lithium carbonate, dimethyl sulfoxide, dilithium silicate, hexafluoroisopropanol, tetrahydrofuran and lithium chloride are added into a water solution, heated and stirred to be dissolved, and cooled to the room temperature; (2) then, polyvinylpyrrolidone is added and stirred to be dissolved to obtain a spinning solution; (3) electrostatic spinning is carried out on the obtained spinning solution; (4) a copper net is used as a receiver to obtain the fiber membrane, and the obtained fiber membrane is impregnated with ethyl alcohol for 3h. The PVDF porous nanofiber membrane prepared through the method has the corrosive resistance to solutions, the good membrane-forming performance and the good interfacial compatibility.

The invention provides a preparation method for ion battery porous diaphragm and an ion battery. The method comprises the steps of dispersing a polymer and a pore former into a solvent I, thereby obtaining the solution containing complex, wherein the polymer is selected from one or more of polyvinylidene fluoride, poly(vinylidene fluoride-hexaflouropropylene)copolymer and polyaramid, the pore former is selected from alkali metal salt, total mass of the polymer and the pore former occupies 1-40% of the solution, a molar ratio of the pore former and the polymer is 0.05-5:1, and the solvent I isselected from at least one of N-Methyl pyrrolidone, N, N-dimethylacetamide, N, N-dimethylformamide, acetone, triethyl phosphate, hexamethylphosphoramide, tetramethylurea, sulfolane and dimethyl sulfoxide; coating the solution and carrying out drying to obtain initial diaphragm, washing the initial diaphragm through utilization of a solvent which cannot dissolve the polymer, and carrying out drying. The method is simple. Thickness, a pore size and porosity of the porous diaphragm can be adjusted. Mechanical strength can be controlled. Mechanical strength is relatively high. Relatively high charge / discharge performance is achieved.

The invention relates to a cleaning agent for cleaning a 3D type sand printing head and a preparation method of the cleaning agent. The cleaning agent for cleaning the 3D type sand printing head comprises the following components in percentage by weight: 30-40% of sec-amyl alcohol, 18-26% of tetramethylurea, 18-22% of dipropyl ether, 6-14% of pinacolone, 9-15% of valerone and 0.6-1.4% of a stabilizing agent, wherein the stabilizer is propylene glycol methyl ether. The cleaning agent has the beneficial effects that raw materials relatively mild to human bodies and production environments are selected to reduce harms to the bodies and the environments to the utmost extent; the cleaning agent is small in surface tension and viscosity and strong in osmotic force, and can quickly dissolve resin crystals in the 3D-type sand printing head to ensure that the patency rate of an ore canal in the printing head is not less than 98.5%; the cleaning agent is stable in chemical property and cannot cause swelling and corroding actions on other parts of the printing head; the cleaning agent can reduce the production cost and prolong the service life of the 3D type sand printing head.

The invention discloses an anode material of a lithium battery. The anode material is prepared from the following components in percent by mass: 62-80% of an anode active substance, 5-10% of a binder,5-12% of a conductive agent, 3-6% of a conductive enhancer, 0.2-1% of a dispersant, 1-3% of an auxiliary agent and 2-6% of a mixed solvent, wherein the mixed solvent is a mixture of N,N-dimethylacetamide, dimethyl sulfoxide, tetramethylurea, trimethyl phosphate, dimethylformamide and water. According to the anode material disclosed by the invention, the lithium battery is excellent in high temperature performance, high in capacity retention ratio, good in circulating performance and long in service life.

The invention provides preparation of a novel nucleic acid dye for polyacrylamide gel electrophoresis. Following reactions are sequentially conducted:, wherein is 4-methylquinoline, and is 6-bromohexanoic acid; , wherein is 2-(methylmercapto)benzothiazole, and is methyl p-toluenesulfonate; , wherein DMF is N,N-dimethyl formamide, Et3N is triethylamine, and HCl(conc.) is concentrated hydrochloric acid; , wherein is 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU), DIPEA is N, N-diisopropyl ethylamine, is taurine, and is a product compound. Improvement is conducted on a molecular structure, therefore, the nucleic acid dye can easily penetrate into a high-density high polymer, the high sensitivity and high stability of the nucleic acid dye are kept, and the technical problem that a fluorescent dye serving as a nucleic acid gel dye is difficult to penetrate into the high polymer and the problem that the nucleic acid dye generally has the high toxicity are solved.

A developing solution for a polyimide precursor containing N,N,N′,N′-tetramethylurea and a lower alcohol having 1 to 5 carbon atoms. The developing solution increases a development margin and results in little or no decrease of the film thickness of a polyimide-based resin film. A development processing method of a photosensitive polyimide resin composition including developing a photosensitive polyimide precursor resin composition, at least a part of which is exposed, with the developing solution; and a pattern formation method including forming a coating film or molding including a photosensitive polyimide precursor resin composition, selectively exposing the coating film or molding, and developing the exposed coating film or molding by the development processing method.

The invention belongs to the field of polymeric nanocomposite material synthesis, and relates to preparation and application of an amino-functionalized graphene oxide / azo polymer composite waveguide material. The preparation comprises the following steps: firstly preparing azo chromophore 4-(4-nitro-alkenyl)phenyl-1,3-diamine from paranitroaniline and m-phenylenediamine, and then preparing a isocyano-terinated azobenzene prepolymer from NAPD and IPDI in the presence of T-12; afterwards ultrasonically exfoliating graphite oxide to obtain graphene oxide dispersion liquid, and reacting with quadrol under the action of 2-(7-azo benzo triazole)-N, N, N minute, N minute-tetramethyluronium hexafluorophosphate, so as to obtain amino-functionalized graphene oxide; adding the carbimide radical blocked azobenzene prepolymer into EAGO, and performing vacuum drying. A thermo-optical coefficient (dn / dT) of the prepared amino-functionalized graphene oxide / azo polymer composite waveguide material is greater than that of a common organic material and is more than 10 times that of a traditional inorganic material, and the composite waveguide material can be applied to the development of novel digital thermal optical switches with low drive efficiency and higher response speed.

A representative printable composition comprises a liquid or gel suspension of a plurality of substantially spherical semiconductor particles; and a first solvent comprising a polyol or mixtures thereof, such as glycerin; and a second solvent different from the first solvent, the second solvent comprising a carboxylic or dicarboxylic acid or mixtures thereof, such as glutaric acid. The composition may further comprise a third solvent such as tetramethylurea, butanol, or isopropanol. In various embodiments, the plurality of substantially spherical semiconductor particles have a size in any dimension between about 5 nm and about 100μ. A representative composition can be printed and utilized to produce diodes, such as photovoltaic diodes or light emitting diodes.

The invention provides a polymer prodrug micelle with reduction responsiveness as well as a preparation method and application thereof, belonging to the technical field of biological medicines. The polymer prodrug micelle is prepared from a prodrug polymer with a structure as shown in a formula (I) which is described in the specification. According to the method, 7-7'-dithiodiheptanoic acid and methyl di-3-aminophenylcarbonate are taken as raw materials, 1-hydroxy-7-azobenzotriazole and 2-(7-oxybenzotriazol)-N,N,N',N'-tetramethylurea hexafluorophosphate are taken as condensing agents, N,N-diisopropylethylamine is taken as a catalyst, a microwave technology is adopted for realizing condensation polymerization, and pegylation is conducted to obtain the polymer prodrug micelle. The preparation method is rapid, simple and convenient inprocess and friendlyto environment, and has the potential of realizing batch production; and the polymer prodrug micelle has a good treatment effect on humancolon cancer cells, and shows good application prospects.

The invention relates to a method for treating carboxylic acid-containing DMF in sucralose production. The method comprises the following steps of: a, adding a small amount of sodium hydroxide into carboxylic acid-containing DMF recovered in sucralose production so as to enable the sodium hydroxide to react with the carboxylic acid-containing DMF, performing evaporating and condensing to obtain amixture containing carboxylic acid, DMF, DMA and DMAC; b, adding sodium hydroxide with an equal molar ratio into the mixture for neutralization reaction, evaporating and concentrating a reaction solution to obtain a white sodium acetate fiinshed product, and condensing evaporated gas to obtain a DMF solution without carboxylic acid; c, conveying the DMF solution without carboxylic acid into a first rectifying tower for distillation, carrying out gas-phase condensation at the top of the tower to obtain a water-containing DMF mixture, and obtaining a mixture of DMAC, tetramethylurea and impurities at the bottom of the tower; d, dehydrating the water-containing DMF mixture, and carrying out secondary rectification to obtain high-purity DMF; and e, rectifying the mixture of the bottom of the first rectifying tower again to obtain DMAC and residual liquid containing DMAC and tetramethylurea. The method has the advantages of simple process and high DMF recovery efficiency, and can avoid thegeneration of solid salt slag in traditional processes, reduce the production cost, and reduce the pollution.

The invention relates to the field of organic chemistry and in particular relates to a spiro-oxindole gamma-butyrolactone compound IV. The spiro-oxindole gamma-butyrolactone compound IV is prepared by taking an acid shown as a formula I and acetone shown as a formula II as raw materials, and taking dichloromethane as a solvent in the presence of N,N'-carbonyl diimidazole shown as a formula III, p-toluene sulfonic acid and cesium carbonate, reacting at 25 DEG C for 4h, concentrating a reaction solution, eluting by column chromatography, collecting eluting solution parts of all detected products and carrying out rotary evaporation to remove the solvent. The invention further provides a spiro-oxindole gamma-butyrolactone compound VI which is prepared by taking the acid shown as the formula I and N-substituted isatin shown as a formula V as raw materials, and taking tetrahydrofuran as a solvent in the presence of 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate and triethylamine, reacting at 0 DEG C for 6h, concentrating a reaction solution, eluting by column chromatography, collecting eluting solution parts of all detected products and carrying out rotary evaporation to remove the solvent. A synthesis method has the advantages of relatively good yield, wide substrate applicable range, simplicity and convenience for operation, moderate reaction, convenience for post-treatment and the like.

The invention discloses a modified composite oxide catalyst and a modification method. The catalyst comprises a catalyst precursor shown in a following general formula, wherein X is at least one of Nb, Sb, Te, Ce, La, Nd, Sm, Cs and Ge; Y is at least one of Mg, Ca, Sr and Ba; a is 1-10; b is 0-6; c is 0-7; d is 0-4; e is 0-5; f is a value determined by n oxidation state of the composition elements; Z is simple substance silicon; wherein the catalyst precursor is activated by the following steps: 1)according to weight of the catalyst precursor, adding 5-100wt% of hexamethyl phosphoric triamide, dimethyl sulfoxide, N,N-dimethyl formamide, carbonic acid-1,2-propylene, sulfolane, N-methyl 2 pyrrolidone, 1,1,3,3-tetramethylurea and lactic acid; 2)drying for 2-28 hours at 60-250 DEG C in oxygen containing gas; 3)forming; and 4)calcinating for 1-24 hours under 350-410 DEG C in oxygen containing gas. Mo12VaCubWcXdYeOf / Z (1).

The invention belongs to the technical field of biology and medicine, and discloses a preparation method of a prodrug of endopeptidase activated doxorubicin. The preparation method is characterized by comprising the following steps: step (1), N-carbobenzoxy-tripeptide is weighed, 1-hydroxyl benzotriazole, 2-(7-azo benzotriazole)-tetramethylurea hexafluoride phosphate, and N,N-dimethyl formamide are sequentially added to the N-carbobenzoxy-tripeptide, bathed in ice and mixed, and then N-methyl morpholine is added for a reaction; step (2), doxorubicin hydrochloride is added, the N,N-dimethyl formamide is replenished for the reaction at the room temperature, a thin-layer chromatography method is used for monitoring the fluorescence intensity of product points until the fluorescence intensity is no longer increased, and then the reaction stops; and step (3), a column chromatography method is used for purification. The prodrug of the endopeptidase activated doxorubicin prepared through the method is low in toxicity, high in purity and capable of being used in the anti-tumor field.

The invention provides an apolipoprotein A1 (ApoA1) determination kit, which contains a reagent R1 and a reagent R2, wherein the reagent R1 is prepared from the following components: a 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) buffer solution, NaCl, guanidine hydrochloride, sodium decyl sulfate, tetramethylurea, polyethylene glycol 6000, a surfactant and a preservative, and the reagent R2 is prepared from a 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) buffer solution, goat anti-human ApoA1 antibody coated latex particles, a surfactant, a stabilizer and a preservative. The invention also provides a preparation method and application of the kit, wherein the kit is beneficial to exposure of antigen sites in lipoprotein and promotion of antigen-antibody reaction due to mutualsynergy of multiple components, and is a liquid kit with strong stability, high sensitivity, good repeatability and low cost.

The invention relates to a tedizolid antibiotic tracing fluorescent probe and application thereof, and belongs to the field of fine chemical engineering. Under the action of O-benzotriazole-tetramethylurea hexafluophosphate, the tedizolid antibiotic tracing fluorescent probe can be dewatered to form an ester bond which connects a fluorophore with tedizolid, and a functioning process of the tedizolid in human cells can be traced through fluorescence microimaging. The tedizolid antibiotic tracing fluorescent probe has the advantages that studies of a metabolic process of the tedizolid in the human cells and a microenvironment where target protein is located have great importance to study on follow-up new medicines.

The invention relates to a preparation method of a polysulfone or polyether sulfone hollow fibrous membrane, a latent solvent composition and the polysulfone or polyether sulfone hollow fibrous membrane. The preparation method comprises the following steps: preparing the polysulfone or polyether sulfone, the latent solvent composition and a non-solvent into a homogenous film-forming solution; introducing the film-forming solution together with a core solution into a cooling bath through an intubation-tube sprayer, separating composite phase to obtain a polysulfone or polyether sulfone hollow fibrous membrane; removing the latent solvent composition or non-solvent from the hollow fibrous membrane, thus obtaining the hollow fibrous membrane. The latent solvent composition is one or mixture of more selected from gamma-butyrolactone, epsilon-caprolactone, epsilon-hexanolactam, triethyl phosphate and tetramethylurea. The hollow fibrous membrane has high density, high separation precision, high flux and excellent chemical resistance.

The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N'-Dicyclohexylcarbodiimide, N, N'-Diisopropylcarbodiimide, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Benzotriazol-1-yl-oxy-tris (dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin ~200 times faster than does mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. It takes 2-4 hours for mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about ~50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and thus avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.

The invention discloses a positive electrode material for a lithium battery, and the material comprises a positive electrode active substance, a binder, a conductive agent, a conductive enhancer, a dispersing agent and a slurry mixing solvent, wherein the mass percentages of all components are as follows: 60-80% of the positive electrode active substance; 5-10% of the binder, 6-12% of the conductive agent, 4-6% of the conductive enhancer, 0.25-1% of the dispersing agent, 1-3% of an auxiliary agent and 3-6% of the slurry mixing solvent. The slurry mixing solvent is a mixed solvent formed by mixing N, N-dimethylacetamide, dimethyl sulfoxide, tetramethylurea, trimethyl phosphate, dimethylformamide and water. The material achieves the purposes that the lithium battery is moderate in cost, thehigh-temperature performance is excellent, the capacity retention ratio is high, the cycle performance is good and the service life is long.

The invention provides an anti-cancer tetravalent platinum complex capable of inhibiting inflammation and immune escape and a preparation method, and particularly relates to the field of biological medicine. The molecular structure of the anti-cancer tetravalent platinum complex is as follows: S1, reacting a divalent platinum complex with hydrogen peroxide H2O2 to obtain a tetravalent platinum complex; S2, mixing the tetravalent platinum complex obtained in the step S1 with O-benzotriazole-N, N, N ', N'-tetramethylurea tetrafluoroboric acid (TBTU) and triethylamine (TEA) in an N, N-dimethylformamide (DMF) solution, and uniformly stirring and mixing; S3, after the reaction is finished, collecting a filtrate, concentrating the filtrate to 0.5-5mL, dropwise adding a mixture of ethanol and water, and centrifugally collecting precipitates; and dissolving the precipitate in methanol, washing the precipitate with diethyl ether for three times, and carrying out vacuum drying to obtain the target product. The tetravalent platinum complex disclosed by the invention not only has very strong toxic activity to tumor cells, but also inhibits inflammation and immune escape through a plurality ofaction targets, and shows an excellent anti-tumor effect in vivo.

The invention relates to a preparation method of an argatroban intermediate (2R,4R)-1-[NG-nitro-N2-(3-methyl-8-quinolinyl sulfonyl)-L-arginyl]-4-methylpiperidine-2-ethyl formate (shown in the figure described in the description). Starting materials N2-(3-methyl-8-quinolinyl sulfonyl)-NG-nitro-L-arginine and (2R,4R)-4-methylpiperidine-2-ethyl formate are dissolved in an organic solvent, a condensation promoter and a condensation agent are added, an amidation reaction is completed to obtain the target product. The adopted condensation promoter is composed of 1-hydroxybenzotriazole and a tertiary amine, the condensation agent is O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), or O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophospate (HBTU), or benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP). The method makes the feeding capacity of the chiral raw material (2R,4R)-4-methylpiperidine-2-ethyl formate reduced, reduces the cost, is fast in reaction rate and simple to operate, increases the yield, and is beneficial for industrialized production.

The invention provides a preparation method of a fluorocarbon release agent. The preparation method comprises the following steps: mixing a perfluoroalkyl acrylate copolymer emulsion, hydrophilic amino silicone oil, a polyoxyethylene polyoxypropylene ether compound, benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate, N-methoxyethyl-N-methyl diethyl ammonium tetrafluoroborate and N-[3-(dimethylamino)propyl]docosanamide, and then carrying out high-speed emulsification so as to obtain the fluorocarbon release agent.

The invention discloses a synthetic method of trifluoroacetyl tripeptide-2. According to the synthetic method, NH2-Val-Tyr(tBu)-Val-Wang Resin resin peptide is synthesized firstly through Wang Resin,then resin peptide is reacted with 6-chlorobenzotriazole-1,1,3,3-tetramethylurea hexafluorophophate, 1-hydroxybenzotriazole, trifluoroacetic acid and N, N'-diisopropylethylamine to synthesize N-(2,2,2-trifluoroacetyl)-Val-Tyr(tBu)-Val-Wang Resin, finally cutting treatment, purification and freeze drying are conducted on N-(2,2,2-trifluoroacetyl)-Val-Tyr(tBu)-Val-Wang Resin, and thus trifluoroacetyl ripeptide-2 is obtained. According to the synthetic method, trifluoroacetic acid which is low in cost and easy to get is adopted to replace trifluoroacetic acid ethyl ester or trifluoro-acetic chloride which is relatively high in cost, meanwhile, the technology that trifluoroacetic acid is activated in firstly and then acidity is neutralized is adopted, the influence of trifluoroacetic acid toNH2-Val-Tyr(bTu)-Val-Wang Resin is overcome, the synthetic method has the advantages of being low in cost, high in efficiency and simple in method, and is an ideal synthetic method of trifluoroacetyltripeptide-2.

The invention relates to a method for synthesizing 3,5-dichloroanisole from 1,3,5-trichlorobenzene, which comprises:a) the reaction between 1,3,5-trichlorobenzene and a methanolate of an alkaline or alkaline-earth metal in a first solvent chosen from among dimethylsulfoxide and 1,1,3,3-tetramethylurea;b) the precipitation of the product resulting from step a) in a second solvent which is not included among substances considered carcinogenic, mutagenic and / or toxic for reproduction by Regulation (EC) n° 1272 / 2008 of the European Parliament and of the Council of 16 Dec. 2008; thenc) the recovery of the precipitate thus obtained.Application: synthesis of 1,3,5-triamino-2,4,6-trinitrobenzene of which 3,5-dichloroanisole is an intermediate product.